Xue Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xue Gao has a total of 267 co-authors. Here are the top co-authors by number of shared publications:
- Yi Tang
University of California Los Angeles
12 shared publications Peng Wang
Department of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California 90095, USA
7 shared publications- Christopher T. Walsh
Department of Biological Chemistry and Molecular Pharmacology
6 shared publications Jie Yang
Department of Chemical and Biomolecular Engineering Rice University Houston TX 77005 USA
6 shared publicationsQiuyue Nie
Department of Chemical and Biomolecular Engineering
6 shared publicationsChunxiao Sun
Department of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, PA, USA
5 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Springer Nature in Nature Biotechnology
- p. 1-12
Adaptive model-guided protein evolution with sparse data optimizes compact eukaryotic genome editors
- 24 August 2026
- Published by Springer Nature in Nature Biotechnology
- p. 1-12
Open AccessAdaptive model-guided protein evolution with sparse data optimizes compact eukaryotic genome editors
- 2 August 2026
- Published by Springer Nature
- p. 163-180
Constructing Drive-and-Process (DAP) CRISPR Guide RNA Arrays for Multiplexed Base- and Prime-Editing
- 2 August 2026
- Published by Springer Nature
- p. 163-180
Constructing Drive-and-Process (DAP) CRISPR Guide RNA Arrays for Multiplexed Base- and Prime-Editing
- 30 June 2026
- Published by Springer Nature in Nature Biotechnology
Prime editing for precise genome engineering and modulation of fungal metabolism
Prime editing has not been established in filamentous fungi, which are major ecological contributors and industrial hosts with vast biosynthetic capacity. Here we develop fPE7max, a prime editing platform optimized for fungi, which supports different edit types, including base substitutions and defined small insertions or deletions, with an average editing efficiency approaching 90%, across diverse genomic loci and species. fPE7max further enables larger insertions of up to 1 kb and deletions of up to 10 kb. We perturb upstream open reading frames in the pleiotropic regulator gene, laeA, to modulate metabolic output across multiple fungal species. Metabolomic profiling reveals activation of previously lowly biosynthetic pathways, leading to the identification of 18 metabolites, including 8, to our knowledge, previously unreported structures, 3 of which with cytotoxic activity. These results establish fPE7max as an efficient platform for genome engineering in filamentous fungi and show upstream open reading frame editing as a strategy for modulating endogenous regulatory networks and accessing the fungal chemical repertoire.
- 30 June 2026
- Published by Springer Nature in Nature Biotechnology
Prime editing for precise genome engineering and modulation of fungal metabolism
Prime editing has not been established in filamentous fungi, which are major ecological contributors and industrial hosts with vast biosynthetic capacity. Here we develop fPE7max, a prime editing platform optimized for fungi, which supports different edit types, including base substitutions and defined small insertions or deletions, with an average editing efficiency approaching 90%, across diverse genomic loci and species. fPE7max further enables larger insertions of up to 1 kb and deletions of up to 10 kb. We perturb upstream open reading frames in the pleiotropic regulator gene, laeA, to modulate metabolic output across multiple fungal species. Metabolomic profiling reveals activation of previously lowly biosynthetic pathways, leading to the identification of 18 metabolites, including 8, to our knowledge, previously unreported structures, 3 of which with cytotoxic activity. These results establish fPE7max as an efficient platform for genome engineering in filamentous fungi and show upstream open reading frame editing as a strategy for modulating endogenous regulatory networks and accessing the fungal chemical repertoire.
- Open Access
- 28 February 2026
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 99, 103470
Advances in multiplex precision genome editing in eukaryotic and prokaryotic systems
- 28 February 2026
- Published by Elsevier in Current Opinion in Biotechnology
- Vol. 99, 103470
Open AccessAdvances in multiplex precision genome editing in eukaryotic and prokaryotic systems
- 14 January 2026
- Published by Elsevier in Molecular Therapy
- Vol. 34 (4) , 2343-2360
Precision A3G base editors for disease modeling and correction
- 14 January 2026
- Published by Elsevier in Molecular Therapy
- Vol. 34 (4) , 2343-2360
Precision A3G base editors for disease modeling and correction
- 23 June 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (12) , 1938-1947
A class of benzofuranoindoline-bearing heptacyclic fungal RiPPs with anticancer activities
Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a promising source of new pharmaceuticals, yet the therapeutic potential of fungal RiPPs remains largely underexplored. Here we report asperigimycins as a distinct class of fungal RiPPs, featuring a unique heptacyclic scaffold consisting of a benzofuranoindoline core and three additional macrocycles, primarily assembled by six distinct fungi-specific DUF3328 oxidases. Inspired by the enhancement of anticancer activity through the N-terminal pyroglutamate in naturally occurring asperigimycins C and D, we chemically modify the inactive asperigimycin B with a series of lipid substitutions at its N-terminus. A derivative with a C-11 linear fatty acid, 2-L6, achieves nanomolar anticancer potency comparable to that of clinically approved antileukemia drugs. High-throughput CRISPR screening identifies the SLC46A3 transporter as a critical factor mediating 2-L6 cellular uptake into human cells. Our findings highlight the promise of engineering asperigimycins as therapeutic leads for cancer treatment.
- 23 June 2025
- Published by Springer Nature in Nature Chemical Biology
- Vol. 21 (12) , 1938-1947
A class of benzofuranoindoline-bearing heptacyclic fungal RiPPs with anticancer activities
Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a promising source of new pharmaceuticals, yet the therapeutic potential of fungal RiPPs remains largely underexplored. Here we report asperigimycins as a distinct class of fungal RiPPs, featuring a unique heptacyclic scaffold consisting of a benzofuranoindoline core and three additional macrocycles, primarily assembled by six distinct fungi-specific DUF3328 oxidases. Inspired by the enhancement of anticancer activity through the N-terminal pyroglutamate in naturally occurring asperigimycins C and D, we chemically modify the inactive asperigimycin B with a series of lipid substitutions at its N-terminus. A derivative with a C-11 linear fatty acid, 2-L6, achieves nanomolar anticancer potency comparable to that of clinically approved antileukemia drugs. High-throughput CRISPR screening identifies the SLC46A3 transporter as a critical factor mediating 2-L6 cellular uptake into human cells. Our findings highlight the promise of engineering asperigimycins as therapeutic leads for cancer treatment.
- Open Access
- 11 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Author Correction: Orthogonal and multiplexable genetic perturbations with an engineered prime editor and a diverse RNA array
- 11 February 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1
Open AccessAuthor Correction: Orthogonal and multiplexable genetic perturbations with an engineered prime editor and a diverse RNA array
- Open Access
- 30 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Orthogonal and multiplexable genetic perturbations with an engineered prime editor and a diverse RNA array
Programmable and modular systems capable of orthogonal genomic and transcriptomic perturbations are crucial for biological research and treating human genetic diseases. Here, we present the minimal versatile genetic perturbation technology (mvGPT), a flexible toolkit designed for simultaneous and orthogonal gene editing, activation, and repression in human cells. The mvGPT combines an engineered compact prime editor (PE), a fusion activator MS2–p65–HSF1 (MPH), and a drive-and-process multiplex array that produces RNAs tailored to different types of genetic perturbation. mvGPT can precisely edit human genome via PE coupled with a prime editing guide RNA and a nicking guide RNA, activate endogenous gene expression using PE with a truncated single guide RNA containing MPH-recruiting MS2 aptamers, and silence endogenous gene expression via RNA interference with a short-hairpin RNA. We showcase the versatility of mvGPT by simultaneously correcting a c.3207C>A mutation in the ATP7B gene linked to Wilson’s disease, upregulating the PDX1 gene expression to potentially treat Type I diabetes, and suppressing the TTR gene to manage transthyretin amyloidosis. In addition to plasmid delivery, we successfully utilize various methods to deliver the mvGPT payload, demonstrating its potential for future in vivo applications.
- 30 December 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-12
Open AccessOrthogonal and multiplexable genetic perturbations with an engineered prime editor and a diverse RNA array
Programmable and modular systems capable of orthogonal genomic and transcriptomic perturbations are crucial for biological research and treating human genetic diseases. Here, we present the minimal versatile genetic perturbation technology (mvGPT), a flexible toolkit designed for simultaneous and orthogonal gene editing, activation, and repression in human cells. The mvGPT combines an engineered compact prime editor (PE), a fusion activator MS2–p65–HSF1 (MPH), and a drive-and-process multiplex array that produces RNAs tailored to different types of genetic perturbation. mvGPT can precisely edit human genome via PE coupled with a prime editing guide RNA and a nicking guide RNA, activate endogenous gene expression using PE with a truncated single guide RNA containing MPH-recruiting MS2 aptamers, and silence endogenous gene expression via RNA interference with a short-hairpin RNA. We showcase the versatility of mvGPT by simultaneously correcting a c.3207C>A mutation in the ATP7B gene linked to Wilson’s disease, upregulating the PDX1 gene expression to potentially treat Type I diabetes, and suppressing the TTR gene to manage transthyretin amyloidosis. In addition to plasmid delivery, we successfully utilize various methods to deliver the mvGPT payload, demonstrating its potential for future in vivo applications.
- 16 December 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (1) , 548-556
Enzymatic Ring Contraction for the Biosynthesis of Sulfur-Containing Cyclopentachromone
Cyclopentachromone, distinguished by its 6/6/5 heterotricyclic ring structure, is a key building block in many bioactive natural products, yet its enzymatic origin remains unclear. We identified a new class of cyclopentachromone-containing compounds, termed isochromosulfines, characterized by unique C-S bonds. A distinct FAD-dependent monooxygenase, IscL, was identified to catalyze the formation of the 6/6/5 cyclopentadiene intermediate, 2S-remisporine A, from a 6/6/6 xanthone precursor via benzene ring contraction. The high reactivity of 2S-remisporine A further promotes a spontaneous thiol-Micheal addition reaction with thiol-containing compounds, forming the C-S bond in isochromosulfines. Additionally, we demonstrate that IscL homologues mediate a bifurcated pathway of benzene ring modification in the xanthone intermediate, leading to either ring contraction or cleavage, which is determined by a critical residue at position 230 to be phenylalanine or tyrosine. Our findings highlight the pivotal role of IscL in forming the 6/6/5 cyclopentachromone scaffold and offer deep insights into its catalytic mechanism. Our work lays the foundation for genome mining of cyclopentachromone-containing compounds and shows the potential application of IscL in biocatalysis.
- 16 December 2024
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 147 (1) , 548-556
Enzymatic Ring Contraction for the Biosynthesis of Sulfur-Containing Cyclopentachromone
Cyclopentachromone, distinguished by its 6/6/5 heterotricyclic ring structure, is a key building block in many bioactive natural products, yet its enzymatic origin remains unclear. We identified a new class of cyclopentachromone-containing compounds, termed isochromosulfines, characterized by unique C-S bonds. A distinct FAD-dependent monooxygenase, IscL, was identified to catalyze the formation of the 6/6/5 cyclopentadiene intermediate, 2S-remisporine A, from a 6/6/6 xanthone precursor via benzene ring contraction. The high reactivity of 2S-remisporine A further promotes a spontaneous thiol-Micheal addition reaction with thiol-containing compounds, forming the C-S bond in isochromosulfines. Additionally, we demonstrate that IscL homologues mediate a bifurcated pathway of benzene ring modification in the xanthone intermediate, leading to either ring contraction or cleavage, which is determined by a critical residue at position 230 to be phenylalanine or tyrosine. Our findings highlight the pivotal role of IscL in forming the 6/6/5 cyclopentachromone scaffold and offer deep insights into its catalytic mechanism. Our work lays the foundation for genome mining of cyclopentachromone-containing compounds and shows the potential application of IscL in biocatalysis.